Reporting Guidance for Oncologic 18F-FDG PET/CT Imaging

Article Figures & Data

TABLE 1

Essential Elements of ¹⁸F-FDG PET/CT Reporting

Element	Description
Clinical history	Indication for study
	Cancer type and site, if applicable
	Brief review of treatment history, if applicable
Technique/procedure	Radiopharmaceutical name
	Radiopharmaceutical dose/activity
	Route of radiopharmaceutical administration
	Uptake time (i.e., from radiopharmaceutical injection to imaging)
	Blood glucose level
	Ancillary medications administered, if applicable
	Precise body region scanned
	CT technique (including whether oral or intravenous contrast was used; if used, name and volume of agent)
Comparison studies	Whether comparison was made with prior PET or PET/CT studies; include dates when available
	Whether correlation was made with prior non-PET imaging studies (e.g., CT or MR imaging); include dates when available
Findings	Location, size/extent, and intensity of sites of abnormal ¹⁸F-FDG uptake
	Abnormal PET findings correlated with concurrent CT images or correlative imaging studies, if applicable
	Incidental PET findings
	Incidental CT findings
Impression	Clear identification of study as normal vs. abnormal
	Interpretation of findings, rather than just restatement of findings
	Succinct differential diagnosis provided, if applicable
	Recommendations for follow-up studies, if applicable
	Documentation of communication of urgent or emergent findings to referring physician or surrogate